--- title: "中國創新藥 “出海” 勢頭強勁，年內海外授權總金額突破 530 億美元" description: "2026 年，中國創新藥對外商務拓展交易持續升温，年內已發生 44 起對外授權交易，總金額突破 530 億美元，首付款約為 31.23 億美元。" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276961831.md" published_at: "2026-02-26T00:48:55.000Z" --- # 中國創新藥 “出海” 勢頭強勁，年內海外授權總金額突破 530 億美元 > 2026 年，中國創新藥對外商務拓展交易持續升温，年內已發生 44 起對外授權交易，總金額突破 530 億美元，首付款約為 31.23 億美元。 2026 年，中國創新藥對外 BD 交易（商務拓展交易）持續升温、勢頭強勁。醫藥魔方 NextPharma 數據庫顯示，截至 2 月 25 日，年內中國創新藥已發生 44 起對外授權（license-out）交易事件，首付款約為 31.23 億美元，總金額達 532.76 億美元。（證券日報） ### Related Stocks - [159102.CN - 華安恆生生物科技ETF](https://longbridge.com/zh-HK/quote/159102.CN.md) - [516930.CN - 生物科技ETF基金](https://longbridge.com/zh-HK/quote/516930.CN.md) - [520880.CN - 華寶恆生港股通創新藥精選ETF](https://longbridge.com/zh-HK/quote/520880.CN.md) - [159839.CN - 匯添富國證生物醫藥ETF](https://longbridge.com/zh-HK/quote/159839.CN.md) - [159859.CN - 天弘國證生物醫藥ETF](https://longbridge.com/zh-HK/quote/159859.CN.md) - [560600.CN - 方正富邦中證醫藥及醫療器械創新ETF](https://longbridge.com/zh-HK/quote/560600.CN.md) - [588250.CN - 鵬華上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588250.CN.md) - [512010.CN - 易方達滬深300醫藥ETF](https://longbridge.com/zh-HK/quote/512010.CN.md) - [513280.CN - 匯添富恆生生物科技ETF](https://longbridge.com/zh-HK/quote/513280.CN.md) - [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Hangzhou Jiuyuan’s Semaglutide Biosimilar Jikeqin Advances Toward China Market Approval | Hangzhou Jiuyuan Gene Engineering Co Ltd has developed Jikeqin, a biosimilar of semaglutide for weight management. The d | [Link](https://longbridge.com/zh-HK/news/276936312.md) | | China's Jiuyuan Genetic seeks approval for Wegovy biosimilar | Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its biosimilar version of Wegovy in China, ahead of a | [Link](https://longbridge.com/zh-HK/news/276994337.md) | | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/zh-HK/news/276886600.md) | | HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China | HBM Holdings (SEHK:2142) has entered an exclusive partnership with Solstice Oncology for its clinical asset HBM4003 outs | [Link](https://longbridge.com/zh-HK/news/276700073.md) | | CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/zh-HK/news/276549711.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。